drugset / Trial / NCT05295459
Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis in Adults (ENLIGHTEN 2)
RandomizedParallel-groupDouble-blindTreatment
Summary
Multicenter, phase III, randomized, blinded, controlled, parallel group.
Timeline
- Start
- 2022-05-13
- Primary completion
- 2025-04-02
- Completion
- 2025-04-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mometasone furoate | Other / unclassified | 7500 ug | — |